2019 San Antonio Breast Cancer Symposium
The 2019 San Antonio Breast Cancer Symposium (SABCS) will be held from December 10–14, 2019 at the Henry B. Gonzalez Convention Center in San Antonio, Texas.
Related Articles
Bexmarilimab Shows Promise in Tough-to-Treat HR MDS; Phase 3 Planned
Bexmarilimab and azacitidine showed continued tolerability and a high overall response rate in relapsed/refractory higher-risk myelodysplastic syndromes in a phase 2 study.
Participants Explain Rationale for Different IO/TKI Options for ccRCC
During a live event, Daniel M. Geynisman, MD, and participants discussed their answers to a poll on which combination to use for a patient with…
Lenvatinib as a Key First-Line Therapy in RAI-Refractory DTC
Francis P. Worden, MD, discusses his key takeaways for other oncologists treating patients with radioidine-refractory differentiated thyroid cancer.
Exploring the Challenges of Radiopharmaceuticals in Prostate Cancer
Jeffrey Wong, MD, discusses the unmet needs in prostate cancer treatment, especially in regard to radiopharmaceuticals.
Well-Tolerated TLX101 Shows Efficacy in Recurrent Glioma
Preliminary results from the phase 2 IPAX-Linz study show encouraging efficacy and a favorable safety profile for TLX101 in recurrent high-grade glioma.
The Evolving Landscape of Myelofibrosis: Current Understanding and Clinical Patterns
Panelists discuss how evolving insights into myelofibrosis—driven by molecular profiling, risk-adaptive therapy, and emerging treatments—are reshaping clinical practice toward more personalized care, with increasing focus…
Participants Discuss PI3K Inhibitors and Endocrine Resistance in Metastatic Breast Cancer
During a a live event, Virginia Kaklamani, MD, DSc, and participants discussed their experiences using a PI3K/AKT inhibitor in patients with metastatic breast cancer.
Immunotherapy Inches Forward in Head and Neck Cancer Trials
The precise use of immunotherapy agents in locally advanced head and neck squamous cell carcinoma has not been clearly delineated, even in phase 3 trials.
LAURA Study: NGS Testing in Diagnosis of NSCLC
Panelists discuss how the practice-changing LAURA study demonstrates the critical importance of next-generation sequencing in guiding therapeutic decisions for non–small cell lung cancer (NSCLC) patients.
New Phase in Prostate Cancer Fight: Cu-SAR-bisPSMA Trial Begins
The first patient in a phase 2 clinical trial evaluating 67Cu-SAR-bisPSMA for patients with metastatic castration-resistant prostate cancer has been dosed.